Corcept Therapeutics Incorporated (FRA:HTD)

Market Cap	3.39B
Revenue (ttm)	631.70M
Net Income (ttm)	89.20M
Shares Out	n/a
EPS (ttm)	0.74
PE Ratio	38.02
Forward PE	48.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	31.00
Previous Close	31.19
Day's Range	31.00 - 31.42
52-Week Range	29.25 - 105.30
Beta	n/a
RSI	18.40
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HTD

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD